{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:33:08Z","timestamp":1791048788664,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To determine the likelihood of myocardial infarction (MI) in type 2 diabetic patients exposed to rosiglitazone and pioglitazone, separately, compared to other antidiabetic therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A case\u2013control analysis nested within the cohort of type 2 diabetic subjects from the Integrated Healthcare Information Services (IHCIS) claims database. Incident cases of MI were matched to three controls each on age (\u00b15 years), gender, and year of first diabetes diagnosis. Subjects were classified according to their antidiabetic drug exposure in the 3,\u2009&lt;\u20096, 6\u201312, and\u2009&gt;\u200912 months prior to the index date. The adjusted odds ratios of MI were calculated for subjects exposed to rosiglitazone and pioglitazone, separately, compared to other antidiabetic agents. Risk factors adjusted for are age, ACE inhibitors, <jats:italic>\u03b2<\/jats:italic>\u2010blockers, diuretics, nitrates, diagnosis of hyperlipidemia, and hypertension and coronary artery disease (CAD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 891\u2009901 diabetic subjects (9870 cases and 29\u2009610 control) identified from 1999 to 2006 were included in the analysis. The mean age was 63 years for the cases and controls. Compared to those treated with other antidiabetic therapies, the adjusted odds ratio of MI was 1.03 [95%CI: 0.93\u20131.12] for rosiglitazone and 0.92 [95%CI: 0.83\u20131.01] for pioglitazone in the 3 months prior to the index date.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results suggest that the risk of MI in subjects exposed to rosiglitazone or pioglitazone for\u2009\u2264\u200912 months is not different from those exposed to other antidiabetic agents but exposure for\u2009&gt;\u200912 months is associated with 15 and 13% increased risk of MI, respectively. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1640","type":"journal-article","created":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T08:07:21Z","timestamp":1220256441000},"page":"989-996","source":"Crossref","is-referenced-by-count":14,"title":["An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients"],"prefix":"10.1002","volume":"17","author":[{"given":"Carol E.","family":"Koro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinggong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Stender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,9]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"National Institute of Diabetes and Digestive Diseases National Institutes of Health. National Diabetes Statistics.http:\/\/diabetes. niddk.nih.gov\/dm\/pubs\/statistics\/index.htm#7[accessed 17 December 2007]."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.10.1134"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults","volume":"285","author":"Adult Treatment Panel III","year":"2001","journal-title":"JAMA"},{"key":"e_1_2_1_5_2","first-page":"23","article-title":"Insulin resistance, heart disease and inflammation. Identifying the 'at\u2010risk' patient: the earlier the better? The role of inflammatory markers","volume":"132","author":"Koenig W","year":"2002","journal-title":"Int J Clin Pract Suppl"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.2007.S33"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.04.001"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000025403.20953.23"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000054195.35121.5E"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000069272.06194.91"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.7.7810"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.10.1180"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.10.1189"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073394"},{"key":"e_1_2_1_18_2","first-page":"A247","article-title":"Beneficial effects of thiazolidinediones on myocardial infarction risk in patients with type 2 diabetes","volume":"53","author":"Koro CE","year":"2004","journal-title":"Diabetes"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pdS.1356"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1443"},{"key":"e_1_2_1_21_2","first-page":"S39","article-title":"Validation of propensity score matching of ethinyl estradiol\/drospirenone and other oral contraceptive initiators","volume":"15","author":"Eng PM","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1640","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T08:06:52Z","timestamp":1700035612000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1002\/pds.1640"],"URL":"https:\/\/doi.org\/10.1002\/pds.1640","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}